ACROBAT Edge Study of Paltusotine in Acromegaly Met Endpoint

Crinetics announces Paltusotine (for treatment of acromegaly) was observed to be safe and well-tolerated among the 60 participants in the ACROBAT Edge and ACROBAT Evolve Studies.

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

FDA grants rare pediatric disease designation: CRN04777 - investigational, orally available, SST5 agonist developing as treatment for congenital hyperinsulinism.

New Data from Paltusotine and ACTH Antagonist Development Programs- European Congress of Endocrinology

A presentation on the company’s orally administered, small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session at the virtual European Congress of Endocrinology (eECE) on September 8, 2020.

Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) appointments Camille L. Bedrosian, M.D. as an independent member of its board of directors.

Crinetics Pharmaceuticals to Participate in September Investor Conferences

Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below: